As Market Sorts Out AI, I’m Playing 2 Small-Cap Biotechs
I’ve got two biopharma stocks on my radar ahead of earnings.
I’ve got two biopharma stocks on my radar ahead of earnings.
We’re leveraging the market’s pullback and insights from Samsung, Lam Research and Microsoft earnings.
OPEC+ meeting expectations, politician Warsh and other headlines are moving stocks this morning.
The 30-year yield hit a 19-year high, and the earnings reports split the hyperscalers.
Renewed conflict in the Middle East, Microsoft and Meta earnings and other headlines moving stocks this morning.
The shares of Apple ($AAPL) keep going higher because they are NOT spending on AI.
All the money has to go somewhere, so instead of taking it out of the market, they put it into Apple — in the great rotation that has highlighted trading in the last few weeks.
Apple recently had a poor quarter and its shares sold off on the basis of its fundamentals — but it’s now going straight up just due to flows.
Apple’s top and bottom-line growth since 2000 is uninspiring as it is basically a giant company that has not innovated anything for about the last 10-15 years since Steve Jobs died and has conspicuously slowing growth.
Apple is a large cash-generating machine that has lived off of taking price up for its products, buybacks and passive money flows into their stock (because it is such a big index component).
Now it is trading at 40x and at its all-time high — as it has a love fest with momentum-based investors.
This speaks volumes about what the equity markets have become and how things are valued.
I don’t typically short value but I am considering an AAPL short.
(I hope Warren Buffett reads this!)
Position: None
The demand picture remains strong, but market conditions mean focusing on support levels.
A 12% yield sounds better than 3%, until you look at what’s actually generating each payout.
Semiconductor stocks are selling off hard, a scary picture in a key week for earnings. But is the ‘China factor’ really to blame?
The stock has fallen sharply, but opinions remain split. Some see a buying opportunity near key support levels, while others warn the valuation still looks extreme.